Skip to main content
. Author manuscript; available in PMC: 2018 Jul 2.
Published in final edited form as: J Neurosurg. 2017 Oct 6;129(1):35–47. doi: 10.3171/2016.11.JNS161170

Table 3. Late Adverse Events IMRT versus 3DCRT NRG Oncology RTOG 0539 versus NRG Oncology RTOG 0424.

Comparison of CTCAE version 3 grade 2+ late adverse events from IMRT in RTOG-0539 (meningioma) versus 3DCRT on RTOG-0424 (low grade glioma).

Trial n Grade 2+ Grade 2 Grade 3 Grade 4
RTOG 0539 (IMRT) 43 25.6% 25.6% 0 0
RTOG 0424 (3DCRT) 52 43% 33% 8% 2%